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USE OF FECAL AND SEROLOGIC BIOMARKERS IN THE PREDICTION OF 
CLINICAL OUTCOMES IN CHILDREN PRESENTING WITH ABDOMINAL 
PAIN AND/OR DIARRHEA 
SARA M. ROGERSON 
ABSTRACT 	
INTRODUCTION: Abdominal pain and diarrhea are two of the most common pediatric 
complaints. They are often associated with a diagnosis of Crohn Disease or Ulcerative 
Colitis, collectively known as inflammatory bowel disease (IBD). IBD is set of diseases 
with ill-defined pathogenesis but similar clinical presentation. Clinicians rely on 
colonoscopic evaluation to distinguish between the two disorders, and the rate of 
colonoscopies has been increasing over the past several years. With the risks and costs 
associated with colonoscopic evaluation, our study sought to identify physiologic 
variables with significant predictive value in order to better determine those most likely 
to have an abnormal colonoscopy. Those variables could then be incorporated into a 
predictive model to stratify the risk of a patient having an abnormal colonoscopy and be 
used as a decision assist tool for physicians.  
 
METHODS: We conducted a retrospective cohort study examining 443 patients who 
underwent a colonoscopy between the years of 2012 and 2016 at Boston Children’s 
Hospital. Data on demographics, lab work, and stool studies was collected into an online 
database for three separate data sets. It was analyzed using SAS 9.4 and logistic 
regression was performed to identify four variables with the most predictive value 
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relating to abnormal colonoscopy. Those variables were incorporated into a predictive 
model.  
 
RESULTS: Several variables were determined to be statistically significant in the 
prediction of abnormal colonoscopy. The four variables with the most predictive value 
based on calculated odds ratios were family history of IBD in a first-degree relative, 
serum albumin, fecal lactoferrin, and platelet count. When ROC curves were generated to 
validate the model using the four variables for each of the data sets, the area under the 
ROC curve was used to assess the robustness of the predictive model. The area under the 
curve (AUC) for the training data set was .81, the first validation set was .79, and the 
second validation set was .6.  
 
DISCUSSION: ROC curves were generated for each of the data sets in order to assess the 
predictive ability of the model, and the AUCS were calculated. An AUC of 1.0 would 
indicate a predictive model with perfect predictability. The AUC of the model building 
set at .81 and the first validation set at .79 are indicative of a predictive model with strong 
predictive value. The second validation set, used to assess the success of the model on an 
external data set, had an AUC of .6, which is less robust in its predictive value but is of 
more predictive utility than a coin flip. 
 
CONCLUSION:  Logistic regression yielded a parsimonious model consisting of four 
variables with the strongest predictive value in terms of having an abnormal colonoscopy. 
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The variables are metrics that are routinely collected as part of ambulatory and inpatient 
clinic visits. When the model was validated using an external data set, it did not perform 
as well as expected based on the results of the training and first validation set. If the 
robustness of the model can be improved when validated using an external data set, it 
could be of great clinical utility to physicians as a decision assist tool and help to limit the 
number of less clinically indicated colonoscopies being performed in the future.  
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INTRODUCTION 
 
 Abdominal pain and diarrhea are two of the most common complaints in children 
presenting to their primary care providers.  Recurrent abdominal pain occurs in as many 
as 15% of school-aged children, and problems related to defection account for up to 25% 
of outpatient referrals to pediatric gastroenterologists (Sanders et al., 1989) Rasquin-
Weber et al., 1999). Pain and diarrhea can occur as a result of a number of underlying 
disease processes, and the clinical work-up necessary to arrive at a specific diagnosis can 
be morbid to the patient, inconvenient to the parent, and costly to payers in the health 
care system. Inflammatory Bowel Disease (IBD), inclusive of ulcerative colitis (UC) and 
Crohn Disease (CD), results in chronic inflammation in the gastrointestinal (GI) tract. 
Patients presenting with these disorders typically complain of abdominal pain, diarrhea, 
and weight loss. Despite the ongoing efforts of numerous clinicians and researchers, the 
pathophysiology of IBD remains incompletely understood, and therefore a cure eludes us 
(Mulder, Noble, Justinich, & Duffin, 2014). At the present, there are several hypotheses 
regarding the pathogenesis of IBD including an impaired mucosal barrier, dysbiosis (an 
imbalance between the “good” and “bad” flora in the intestinal tract), persistent 
pathogenic infection, as well as immune dysregulation . In several countries with 
historically low rates of IBD, there has been a significant increase in the incidence of 
Crohn disease and ulcerative colitis over the course of the past two decades, and this 
points to increasing environmental pressures unmasking existing genetic vulnerability.  
(Xavier & Podolsky, 2007).  
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Though UC and CD can be similar in presentation, they differ both in the regions 
of the gastrointestinal tract that they involve, as well as the nature of their underlying 
inflammatory processes (Silva et al., 2016).  CD can affect any part of the digestive tract 
extending from mouth to anus, though inflammation related to CD most commonly 
occurs in the ileum or distal small intestine (Baumgart & Carding). In about 20% of 
patients, the histologic findings in patients with CD can manifest as an aggregation of 
macrophages, leading to a finding of non-caseating granulomas (Xavier & Podolsky, 
2007). The often-indolent nature of CD can mask its severity and delay diagnosis.  As 
such, affected children frequently present with long-term systemic symptoms, including 
poor weight gain, stunted linear growth, or a delay in pubertal development.   
In contrast, the inflammation occurring in patients with UC is limited to the colon. 
Crypt abscess, manifest as collections of neutrophils in the crypt space, are typical in 
patients with active UC, and severe inflammation results in the development of extensive 
and confluent mucosal ulcerations (Xavier & Podolsky, 2007). As such, patients with UC 
typically present more acutely with loose and bloody stool, abdominal pain, and fecal 
urgency (Baumgart & Sandborn). 
 Due to similarities in their clinical presentation, it can be difficult to distinguish 
patients with CD from those with UC, and clinicians rely on endoscopic assessment and 
mucosal biopsy to stage the extent and nature of inflammation in each patient.  As such, 
upper endoscopic and colonoscopic evaluation has become the gold standard for use in 
the diagnosis and interval assessment of gastrointestinal disorders in children and adults 
(Tringali, Balassone, De Angelis, & Landi, 2016). In a large multicenter study conducted 
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in the United States investigating pediatric endoscopic practices, the indications for 
colonoscopy were abdominal pain (31%), evidence of GI tract bleeding (31%), and 
diarrhea (24%) (Kawada et al., 2016). As the incidence of IBD has increased, so has the 
frequency of pediatric patients undergoing colonoscopic evaluation. At Boston Children’s 
Hospital, the rate of colonoscopies performed since 2010 has been steadily rising. This 
increase in the number of endoscopic studies is likely being driven in part by parental 
angst and the misperception that more testing yields better clinical care for their children. 
However, there is no data to support this notion. Nor is there any study data 
demonstrating that parents fully understand the likely benefits and risks associated with 
performance of colonoscopic evaluation in their own children.   
 
Figure 1. Colonoscopy Trend at Boston Children’s Hospital Graph displaying the 
increasing number of colonoscopies performed at BCH from 2010-2015.  
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There are inherent risks to any procedure, and this extends to the performance of 
upper endoscopic and colonoscopic evaluations.  Relevant risks related to the 
performance of these procedures include perforation, complications related to anesthesia, 
or morbidity related to the requisite bowel prep. (Thakkar, El–Serag, Mattek, & Gilger, 
2008). In children, there is an approximately 1.1% occurrence of complications relating 
to the performance of a colonoscopy, and this represents a nearly 4-fold increase in the 
rate of complications (0.3%) reported in the adult literature (da Silva, Briars, Patrick, 
Cleghorn, & Shepherd, 1997). These statistics take into account only intra-procedural and 
immediate post-procedural events, without considering the rate of adverse events that 
occur outside of the 12-24 hour peri-procedure window. In a quality improvement study 
done at a children’s hospital in Colorado, they extended the observation period for 
adverse events in patients who underwent endoscopic or colonoscopic evaluation to 72 
hours, and observed a two-fold increase (2.6%) in the incidence of patient-reported 
adverse events (Kramer & Narkewicz, 2016). In addition to the morbidity incurred, 
colonoscopy also represents a significant financial burden to patients and their families.  
Pain-predominant functional gastrointestinal disorders (PP-FGID) such as that 
observed in patients with irritable bowel syndrome (IBS) are common in children. There 
is not much data in the literature that examines rigorously the costs related to the 
diagnosis and management of PP-FGID in pediatric patients. However, previous studies 
in the adult population have estimated that patients with IBS consume up to 50% more 
healthcare resources than those who do not have IBS (Dhroove, Chogle, & Saps, 2010). 
Because colonoscopic studies can be among the most expensive of diagnostic modalities 
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employed in the evaluation and management of these patients, it would be beneficial to 
both patients and medical payors to identify those patients who are most likely to benefit 
from this type of evaluation. In a large multicenter study, data collected from 999 
colonoscopies performed over a 10-year period demonstrated that a significant 
percentage of patients studied were not found to have identifiable pathology to explain 
their symptoms.  As such, colonoscopic evaluation in these patients could have been 
avoided if the clinician had access to information that would have supported a more 
conservative management approach (Kawada et al., 2016).  
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Figure 2: Findings on Colonoscopy from Large Multicenter Study (Kawada et al., 
2016) Chart displaying the pathological findings from colonoscopies performed on 999 
patients. 
 
Predictive Modeling as Screening Tool  
The application of predictive modeling may be a useful approach to help gain a 
better understanding of the relative risks and benefits related to the performance of 
colonoscopic studies. It can be useful in personalized medicine and aid clinicians in the 
decision-making process (Luo, 2016). Clinical prediction has been a facet of medicine 
since the first physicians began basing their practice less on religion and more on rational 
observations, prior experience, and overall clinical impression.  More recently, 
investigators have formalized this process through the development of scoring systems 
that can be used to identify important physiological parameters and chronic health 
conditions that can be used to help predict a patient’s clinical outcome (Rosenfeld & 
Breslow, 2008). Predictive variables are typically identified using well-established 
statistical methods. These variables can be used to derive a scoring system in a particular 
population of clinical patients, and then the validity of the model can be confirmed 
through the application of this scoring system to different study populations and 
demographic groups. Risk stratification using this type of predictive modeling is 
becoming an increasingly common way to address challenges related to allocating 
increasingly limited financial resources to manage patients with chronic illnesses and 
increasing disease complexity.  
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Most private health plans have developed case management programs to both 
improve the delivery of appropriate anticipatory care to high-risk patients, as well as to 
limit the utilization of high-cost interventions.  However, case management 
infrastructures are costly to maintain and often under-equipped to deal with the evolving 
complexity of medical decision-making.   
The application of predictive modeling in was initially employed in the 
development of evidence-based modeling to better evaluate the risk and benefits of 
particular interventions employed in intensive care units.  In this context, predictive 
modeling made use of observable physiological data to stratify acutely ill patients for risk 
of death (Knaus, Draper, Wagner, & Zimmerman, 1985).  In doing so, physicians began 
the transition from making assessments based on global clinical impression to instead 
basing their clinical decisions on an analysis of a well-articulated collection of discrete 
and concurrent physiologic variables (Knaus et al., 1985). One of the most widely 
employed examples of predictive modeling is the Acute Physiologic and Chronic Health 
Evaluation (APACHE) instrument, a metric developed to assess disease acuity in patients 
admitted to the intensive care unit (ICU). In developing this metric, data from a 
population of 5800 patients treated at thirteen different hospitals was collected. 
Subsequent statistical analysis identified 12 discrete continuous physiologic variables that 
could be measured within 24 hours of ICU admission (Rosenfeld & Breslow, 2008). 
These variables were used in combination to help an objective measure of clinical disease 
severity (Knaus et al., 1985).  
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 Predictive modeling is also used in the assessment of patients with cardiovascular 
disease (CVD) (Pencina, D' Agostino, D' Agostino, & Vasan, 2008). The Framingham 
Risk Score, for example, employs variables including age, sex, systolic blood pressure, 
total and HDL cholesterol, and the presence or absence of diabetes mellitus, smoking, 
and electrocardiographic evidence of left ventricular hypertrophy to predict future 
cardiovascular morbidity and mortality (de Ruijter et al., 2009).   
The decision to include a particular clinical variable in a predictive model is based 
on the relationship between the variable, the population of interest, and the outcome of 
interest (Pencina et al., 2008). Once these parameters have been defined, the import of a 
variable is based on the level of statistical significance between itself and the outcome of 
interest (Pencina et al., 2008).  
 
Model Building 
 The components of a predictive model are chosen using a process of logistic 
regression. This process seeks to model the probability that an event does or does not 
occur, depending on the values of one or more independent variables. Predictive 
modeling can also be used to study the effect of a series of variables on a binary response 
variable, as well as to classify observations by estimating the probability that an 
observation is in a particular category (such as an abnormal or normal colonoscopy) 
(Foltz, 2015). Unlike simple linear regression, in which variables are typically 
continuous, the dependent variables employed in logistic regression are categorical or 
binary. Logistic regression estimates the probability of a binary response based on one or 
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more independent, or predictor, variables. The viability of a predictor variable is 
determined using odds ratios, which represent how the odds change with a one-unit 
increase in that variable when all of the other variables have been held constant. For 
example, a one-unit increase in X increases the odds of the event occurring by 1.5, or 
50% (Foltz, 2015). The goal of logistic regression is to estimate the probability (0-1, the 
binary dependent variable) of a particular occurrence based on a linear combination of 
the independent variables. The logit, defined as the natural log of the odds ratios of the 
independent variables, is employed in this process.  Similarly, beta coefficients are 
employed with reported odds ratios, which are themselves coefficients of estimates 
resulting from a regression analysis that has been standardized so that the variances of 
independent and dependent variables are one. The benefit of using these variables rests 
on the fact that the coefficients are indifferent to scale of units related to each of the 
independent variables and thus makes comparison between them easier (Foltz, 2015). As 
such, predictive model equations developed using logistic regression have the basic form 
as follows:  
 
Logit (p) = β0 + β1X1 + β2X2 … 
 
 Once a model has been built, its usefulness needs to be validated, and that is often 
done using a receiver operating-characteristic (ROC) curve.  
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Receiver Operating-Characteristic Curves 
 The basic measure of the accuracy of a diagnostic test is determined by its relative 
sensitivity and specificity (Zou, O’Malley, & Mauri, 2007). The accuracy of a test is 
measured by comparing the results of the test to the true disease status of the patient, i.e. 
did the test correctly predict the presence of a disease when there was empirical evidence 
to verify diagnosis (Obuchowski, 2003). The true disease status is sometimes referred to 
as the “gold standard” because it is the disease status measured without error as 
determined by pathology or clinical follow up (Zou et al., 2007). It is easier to compare 
tests along a single dimension instead of reconciling both the sensitivity and the 
specificity of two tests simultaneously. As such, a measure is needed that combines 
sensitivity and specificity, but does not depend on the presence of disease. A Receiver 
Operating Characteristic (ROC) curve satisfies this criteria by assessing the accuracy of a 
predictive test by representing the probability that if given two subjects (one who will 
develop an event and one who will not), the model will consistently assign a higher 
probability of the occurrence of the event of interest to the former (Pencina et al., 2008). 
The graph of the ROC curve includes an X-axis that is defined as (1-specificity), and a Y-
axis relating sensitivity. The curvilinear shape of the ROC curve illustrates the inverse 
relationship between sensitivity and specificity, as well as how the sensitivity and 
specificity vary together (Obuchowski, 2003). The curve is independent of disease 
prevalence, and it does not depend on the scale of the test results. Higher sensitivity 
typically results in a test with a higher false positive rate. Conversely, higher specificity, 
there is a higher rate of false negatives. The most ideal predictive model will display both 
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high specificity as well as a high sensitivity. The use of an ROC curve enables a direct 
visual comparison of two or more tests on a common set of scales (Obuchowski, 2003).  
The area under the ROC curve (AUC) ranges from 0.0 to 1.0, and the closer the 
area is to 1.0, the better the performance of the test. An area equal to 1.0 represents an 
ideal test that demonstrates both 100% accuracy, as well as 100% specificity. The 
practical lower bound of the AUC is 0.5, which is known as the chance diagonal. A test 
with a predictive outcomes that falls along this line possesses an accuracy comparable to 
a coin flip (Obuchowski, 2003). Alternatively, tests with an AUC that is greater than 0.5 
have some discriminatory ability.  
Previous studies have identified fecal and serologic biomarkers that are indicative 
of active inflammation in the intestine including C-Reactive Protein (CRP), Erythrocyte 
Sedimentation Rate (ESR), and serum albumin.  Lactoferrin (FLA) and calprotectin are 
proteins that can be measured directly in the stool of patients, and changes in their levels 
over time are likely more specific predictors of mucosal inflammation in the 
gastrointestinal tract.   
 
Objectives 
The goal of this retrospective study is to identify which clinical and biochemical 
parameters are most predictive of an abnormal finding at the time of colonoscopy. 
Additional goals of this study will include the development of a predictive model aimed 
at stratifying risk for the likelihood of an abnormal colonoscopy.  Our ultimate goal is to 
develop a decision assist tool that will be of use to clinicians, patients, and parents in their 
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efforts to gain a better understanding of the relative risks and benefits proceeding with 
endoscopic study in a particular patient.  
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METHODS  
 
Study Design 
 
 We performed a retrospective cohort study to determine the variables that are 
most predictive of an abnormal finding at the time of colonoscopy.  
 
Participants 
  Using a search of electronic medical records Boston Children’s Hospital (BCH) 
between January 1, 2012 and June 30, 2016, we identified 350 discrete colonoscopies that 
were performed as part of an evaluation of abdominal pain and diarrhea. All subjects 
were between 1 and 25 years of age and received their primary GI care on the main 
campus at Boston Children’s Hospital or one of its satellites. The demographic 
information for each patient, including medical record number (MRN), date of birth, sex, 
Body Mass Index, ethnicity, race, and IBD diagnosis and date, was abstracted from the 
medical records. Inclusion criteria for this study included a presenting complaint of 
abdominal pain and/or non-bloody diarrhea. Patients were excluded from the study if 
they carried a pre-existing diagnosis of IBD (either ulcerative colitis or Crohn disease), 
celiac disease, allergic colitis, reflux, or had previously undergone an intestinal surgical 
procedure. Patients were not included if they were receiving immunosuppressive therapy 
in the form of steroids or other immunosuppressant drugs, or presented with other 
inflammatory comorbidities, such as juvenile arthritis, Becet syndrome, or familial febrile 
syndromes. Patients were also excluded if the primary reason for performing the 
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colonoscopy was the placement of colonic motility catheters. Data from the 350 patient 
set was allocated into two discrete data sets, data from 212 studies were used to build a 
predictive model, and the data from the remaining 138 studies were used in a model 
validation set.  
 
Data Collection 	 The data gathered from eligible subjects was collected and entered into the 
Research Electronic Data Capture (REDCap) a HIPPA-compliant web-based tool for 
Boston Children’s Hospital. Their information was placed in a Case Report Form (CRF), 
designed to expedite the data collection process and easily facilitate data analysis by 
keeping all of the relevant information in one place. There are sections in the CRF 
dedicated to demographic information, disease phenotype, laboratory results, symptoms, 
and information regarding medications (Figure 3). 
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Figure 3: CRF for Information Collected from Electronic Medical Records. CRF 
demonstrating all of the information gathered on every subject in the study.    
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Collected data included a complete blood count with differential (CBC), liver 
panel, inflammatory markers, stool studies, and stool cultures for routine pathogens 
including Salmonella, Shigella, Yersinia, Campylobacter, Escherichia Coli, and 
Clostridium difficile (C. diff). To be included in the study, the patient must have had at 
least one of the following values present: C-reactive protein (CRP), Fecal Lactoferrin 
(FLA), or erythrocyte sedimentation rate (ESR).  If none of the three variables were 
present, the patient was not included in the study.  We examined the lab work collected 
closest to the initial clinic visit, defined as the first time the patient was seen in the 
Children’s Hospital outpatient clinic or as an inpatient. If there were several sets of lab 
work within two weeks of the relevant clinic date, we examined the set that was the most 
complete. All of the values examined were taken from the same set of lab work, with the 
exception of FLA, which was accepted within 1 month of the clinic visit. Lab work from 
the “follow up” encounter, defined as the patient’s first ambulatory visit post-discharge or 
post-colonoscopy was also examined. There were no parameters for inclusion or 
exclusion regarding the available information in the follow up lab work. All of the 
demographic information for the subject, including vitals, history, age, height, weight, 
etc. was abstracted from the initial clinic visit.  
 
Data Analysis 
The data collected for this study was analyzed using SAS 9.4. Descriptive 
statistics were used to summarize characteristics of patients who completed a 
colonoscopy in both the training and validation data sets. Continuous variables are 
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reported as mean +/- SD or median with interquartile range, and categorical variables 
have been reported as percentages. The training data set was used in model building 
using a scientific method (preexisting knowledge and published results) excluding any 
statistical algorithmic model functions to develop the most parsimonious model.  
 
Model Building 
Scientific methodology and logistic regression yielded a parsimonious model to 
be used in the stratification of risk for having an abnormal colonoscopy. Several variables 
were considered for inclusion in the model derived from clinical utility and previously 
established significance in relation to IBD. Those variables included: family history of 
IBD in first-degree relative, duration of symptoms, location of pain, weight loss reported, 
fatigue, the laboratory results for various values from a CBC with differential, the 
laboratory results of various values from a liver panel, as well as inflammatory markers 
such as CRP, ESR, and fecal inflammatory markers such as FLA and calprotectin. Using 
logistic regression, the odds ratios of each of the variables was determined, and the four 
variables with the highest odds ratios were selected for inclusion in the parsimonious 
model. Once the variables and their coefficients had been determined, the success of the 
model was tested using the data from three data sets, the first of which was a model 
building set, and the second and third which were validation sets.  
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ROC Curve 
The robustness of the model developed to assess the risk of an abnormal 
colonoscopy was examined using an ROC curve. Three curves were generated using SAS 
9.4, one for each data set. The success of the model was evaluated by determining the 
AUC for each of the three ROC curves. 	 	
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RESULTS 
 
 	 For the purposes of this study, 350 subjects who had received a colonoscopy were 
identified using electronic medical records at Boston Children’s Hospital.  The subjects 
were divided in the following ways: 212 used as a training set to build the model, which 
was split 70/30 for the purpose of saving a validation set for the model, and the random 
30% (98 subjects) were used as the first validation set. A second set of 138 subjects who 
fit the criteria were identified and used to build a second validation data set in order to 
prove that the model worked. This totals a population of 443 for the study. Here the 
results of each data set will be discussed.  Values will be presented as follows: Mean ± 
(standard deviation) (SD).  Please reference Table 1 for a summary of the variable values 
in the three data sets.  
 
Training Set 
The average age of subject in the training data set was 13.6 ± 5.1 years, with a 
distribution of 45% male subjects.  Roughly one-third (33%) of the subjects were 
identified as having abnormal pathology from their colonoscopic evaluation. The average 
white blood cell count (WBC) value was 8.24 ± 5.9 cells x103/mL, which is within the 
normal range established by the Food and Drug Administration (FDA) (Food & Drug, 
2016). The average hemoglobin (Hb) value was 12.58 ±1.8 g/dL, and the average platelet 
count was 331.36 ± 128.1 cells x103/mL, and both fell within the normal range for 
children. The average CRP value for the subjects was .89 ± 1.9 mg/L, and the average 
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albumin level was 4.26 ±0.5 g/dL. These levels are indicative of ongoing and active 
inflammation. Fecal lactoferrin, when measured quantitatively, can be described as 
falling between 0-30, 31-100, or >100. A level >30 can be indicative of inflammation in 
the digestive tract. Only 96 subjects from the first set had record of a quantitative 
lactoferrin assay, and of those 58% of subjects fell within 0-30, 20% fell within 31-100, 
and 22% fell >100. Only 10% of the subjects in this data set had a first-degree relative 
with a diagnosis of IBD.  
 
First Validation Set  
93 patients represented a random 30% sample of the original 212 subjects 
identified for the model training data set. The values represented in the model building 
set are closely mirrored by the first validation set. The average age of participant was 
13.4 ± 5.4 years, with 42% of them being males. 40% of these patients were identified as 
having had an abnormal colonoscopy. Their WBC, hemoglobin, and platelet counts for 
these patients were within the normal ranges established for children by the FDA 
guidelines, being 8.04 ±3.2 cells x103/mL, 12.48 ± 1.6 g/dL, and 337.73 ±106.9 cells 
x103/mL, respectively. The average CRP level was 1.39 ± 4.32 g/mL and the albumin 
was 4.23 ±0.5 g/dL. 50 out of 93 of the subjects had completed a quantitative lactoferrin 
assay, 66% of which fell between 0-30, 16% between 31 and 100, and 18% were greater 
than 100. Only 18% of the individuals identified a first-degree relative as having been 
diagnosed with IBD.  
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Second Validation Set 
In the second validation data set collected for this study, 70 (47.9%) of the 
participants were male. The mean age of participant was 14.2 ± 4.5 years. About one 
third (35%) of these patients were found to have an abnormal colonoscopy, and roughly 
two thirds (65%) had normal colonoscopies. Chronic active inflammation of the 
descending colon was the most common abnormality observed at the time of the 
procedure (31, 21.2%) with acute active inflammation of the transverse colon being the 
second most common. In general, acute active inflammation was seen more frequently 
than chronic active inflammation (40.3% vs. 28.5%, respectively) and chronic inactive 
inflammation was the least frequently observed. The participants were seen in the GI 
clinic an average of roughly two times ± 2.33 before they completed the colonoscopy 
leading to their initial diagnosis of IBD. The majority of patients were not admitted to the 
hospital between their initial clinic visit and their colonoscopy. However, of the 19 
patients that were admitted, only three were admitted for issues other than abdominal 
pain and/or non-bloody diarrhea. Of the patients presenting with non-bloody diarrhea 
more than half of them (52.7%) had been experiencing the diarrhea for a period of time 
greater than four weeks. 126 out of 145 patients were experiencing abdominal pain at the 
time of their initial clinic visit, with pain in the left-lower quadrant (LLQ) constituting the 
most frequently observed region. Hypogastric pain was the least frequently reported. 
Most of the participants (66.8%) did not report having a first-degree relative diagnosed 
with intestinal disorders (IBD, irritable bowel syndrome, celiac disease, other) but of 
those who did, IBS was the most commonly reported (12.4%).  
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 The average Hemoglobin and WBC counts fell within the normal range for 
children (12.6 ± 1.7l  g/dL and 7.85 ± 2.8 cells x103/ mL, respectively Additionally, the 
average platelet count was normal at 325.5 ±110.8 cells x103/mL. The average CRP value 
was higher than normal at 1.14 ± 2.4 g/mL with a normal average albumin of 4.24 ± 0.5 
g/dL. Of the 74 patients whose fecal lactoferrin levels were measured quantitatively, 69% 
were in the 0-30 range, 15% were in the 30-100 range, and 16% were in the >100 range.  
 
Table 1: Variables and their Values in the Three Data Sets/ Mean (SD) 
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Normal vs. Abnormal 
 When looking at the set of 443 subjects as a whole, it can be divided into those 
who had a normal colonoscopy (n=287) and those who had an abnormal colonoscopy 
(n=156). The age of the subject does not appear to be a risk factor in the prediction of 
abnormal versus normal colonoscopy, with a p-value of .89.  41% of the normal 
colonoscopies were performed on male subjects, and 54% of the abnormal colonoscopies 
were on male subjects, a significant difference with a p-value of .0086. The difference in 
WBC count between the two groups (7.66 ± 5.1 versus 8.39± 2.8 cells x 103) was not 
significantly different with a p-value of .0523. The hemoglobin value of patients found to 
have a normal colonoscopy, 12.97 ± 1.3 g/dL, differed significantly from those observed 
in patients with abnormal colonoscopies (11.97 ± 1.7, at a p-value of <0.0001). With the 
same p-value, the average platelet count in cells x 103/mL differed significantly between 
the two groups: 297.74 ±74.3 vs. 375.72 ±138.7, respectively. The CRP value of the 
normal group is .49 ± 1.5 g/mL and the value for the abnormal group is 1.43 ± 2.4 g/mL, 
a significant difference with a p-value of <0.0001. For the other values that demonstrate a 
significant difference between the groups that had a normal colonoscopy and an abnormal 
colonoscopy, please refer to Table 2.  
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Table 2. Difference in Variables Observed in Normal and Abnormal Colonoscopies/ 
Mean (SD)  
 
Model Building  
Using logistic regression, a parsimonious predictive model was developed to determine 
the likelihood of a patient having an abnormal colonoscopy. Of the several variables 
considered for inclusion in the model, only the ones that were determined to have 
statistical significance between the normal vs. abnormal colonoscopy groups were 
evaluated for further inclusion in the model. Ultimately, four variables possessed the 
highest odds ratios: IBD Family history in a first-degree relative as a dichotomous 
variable (either yes or no), FLA levels as a dichotomous variable (0-30 or 31-100), serum 
albumin in g/dL as a continuous variable, and platelet count in Kcell/mm3.  FLA is 
usually measured as a continuous variable. If the level is found to exceed 100 it 
approaches a perfect predictor of the presence of active intestinal inflammation indicative 
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of IBD, so it was instead incorporated as a dichotomous variable, excluding the use of 
levels reading >100. ESR and CRP levels were not included in the model. The single 
greatest predictor of an abnormal colonoscopy was family history of IBD in a first-degree 
relative, with an odds ratio of 2.5. Please refer to Table 3 for a list of odds ratios for the 
variables included.  
 
 Table 3: The Four Predictor Variables and their Odds Ratios  
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Model Formula 
 The model formular was generated using the four variables established though the 
process of logistic regression. It appears as such:  
Logit(Abn. Colonoscopy) = ẞ0 + ẞ1(Lactoferrin) + ẞ2(Family Hx of IBD) + 
ẞ3(Albumin) + ẞ4(Platelets) 
If the model was successful, an assessment of an individual patient’s probability 
of having an abnormal colonoscopy could be derived using the values for each of the four 
variables substituted into the formula. Once the model was created, we validated its 
success by generating ROC curves using the model for each of the three data sets, and 
plotting each of the validation sets against the model building set.  
 
Model Validation 
 Using SAS 9.4, an ROC curve was generated for each data set using the model 
formula. Two graphs were generated that plotted each of the validation sets against the 
model building set. The resulting graphs permitted a visual comparison of the 
effectiveness of the model, as well as a calculation of the AUC for all three curves using 
SAS 9.4 The AUC for the training set was .81, the AUC for the first validation set was 
.79, and the AUC for the second validation set was .6.  
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Figure 4. Graph of ROC curve of Validation Set 1 against Training Data Set. Graph 
demonstrating the similarity between the two ROC curves. 
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Figure 5. Graph of ROC curve of Validation Set 2 against Training Set. Graph 
demonstrating the curve for the second data set as compared to the model building set.  
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DISCUSSION 
 	 There are a variety of clinical presentations for which a pediatric 
gastroenterologist would consider recommending colonoscopic evaluation, and 
abdominal pain and diarrhea would be chief among them. However, it has been shown 
that a significant percentage of patients who undergo the procedure do not have 
identifiable pathology (35%). As such, the inherent risk related to the performance of any 
procedure, the relative cost of the procedure, and the potentially high incidence of 
negative findings, there is a need for clinicians to develop better screening procedures 
prior to committing a patient to colonoscopic evaluation.  
We performed a retrospective cohort study on 443 patients who underwent 
colonoscopic evaluation at Boston Children’s Hospital in order to build a predictive 
model aimed at screening out those who are most likely to have a normal colonoscopy to 
limit the number of potentially unnecessary colonoscopies in the future. Using statistical 
analysis, we identified family history of IBD in a first degree relative, fecal lactoferrin 
level, serum albumin level, and platelet count as possessing the highest odds ratios for an 
abnormal study. These four metrics were used to generate ROC curves for each of the 
three data sets, plotting the validation sets against the model building set in order to 
demonstrate the efficacy of the model. Based on the AUC values, where 1.0 demonstrates 
a perfectly accurate prediction, the curve generated from the training set had an AUC of 
.81 and the AUC of the first validation set was .79, and are demonstrated in figure 3. The 
AUC of the second validation set, however, was .6, as shown in Figure 4. As mentioned 
above, a study with an AUC greater than 0.5 possesses a discriminatory ability greater 
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than that of a coin flip. Though the first two ROC curves show promise for the model’s 
predictive ability, the curve for the second validation set was less promising. It is unclear 
why the results differed so drastically in the second validation set, though it may be 
related to the incorporation of albumin. Albumin levels are low in cases of IBD, whereas 
all of the other variables correlate positively with inflammation. The next step moving 
forward would be to identify potential reasons for this loss of precision when the model 
was applied to a new data set.  
There are inherent weaknesses when conducting a retrospective cohort study. Most 
notably, not every subject identified as eligible will have every pertinent variable 
accounted for, as they would in a prospective study. Though the sample size was large at 
443 subjects, this study also took place at a single medical center, and it would be prudent 
to expand the study to include data from patients drawn from multiple centers to observe 
the success of across study practices.  
It is interesting to note that logistic regression analysis did not result in the inclusion 
of ESR and/or CRP in the predictive model. Both of these biomarkers have traditionally 
been considered useful in the diagnosis of IBD, and it is surprising that when included in 
the model they did not increase its predictive ability similar to that of the other variables. 
It is possible that since they are indicative of inflammation in the body, but not 
necessarily the GI tract, their levels are confounded by other systemic processes, unlike 
the fecal lactoferrin levels, which are directly related to the inflammation in the GI tract. 
The objective of the predictive model was the development of a decision assist tool 
for clinicians to use when they are faced with a decision about whether or not to pursue 
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colonoscopic evaluation for a particular patient. The model would help to stratify the risk 
of a patient having an abnormal finding upon colonoscopy, and could potentially inform 
clinician decisions. The results of this modeling are not meant to remove clinical 
prerogative from the patient’s physician, but instead to provide a rationale to assist in the 
decision making process. The parsimonious model described here includes only four 
variables that are routinely collected during GI ambulatory or inpatient visits. This 
modeling could help to identify those patients in the bottom 10% who are least likely to 
have an abnormal colonoscopy, and this would result in a decrease in the number of less 
clinically indicated colonoscopies moving forward. As such, the use of a predictive 
model as a decision assist tool could have great clinical utility in pediatric 
gastroenterology practice, and potentially limit the amount of unnecessary colonoscopies 
being performed.  
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